Clinical Study
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
Table 4
Most commonly reported (≥5% in either treatment group) adverse events.
| | | Bromocriptine-QR
| Placebo
| | | (%) | (%) |
| | Nausea | 386 | 49 (8.0) | | Dizziness | 189 | 53 (8.6) | | Headache | 141 (11.6) | 54 (8.8) | | Fatigue | 170 | 43 (7.0) | | Vomiting | 106 | 21 (3.4) | | Constipation | 69 (5.7) | 31 (5.0) | | Hypoglycemia | 67 (5.5) | 26 (4.2) | | Diarrhea | 92 (7.5) | 49 (8.0) | | Nasopharyngitis | 64 (5.3) | 34 (5.5) | | Upper respiratory infection | 60 (4.9) | 40 (6.5) | | Arthralgia | 47 (3.8)† | 38 (6.2) |
|
|
Between-group difference .
†Between-group difference .
|
